![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
May 28, 2026
ACHIEVE (EA5221) is the first lung cancer clinical trial for older patients with metastatic NSCLC, comparing immunotherapy (pembrolizumab) with and without chemotherapy
May 28, 2026
The latest findings in breast cancer, cardiotoxicity, leukemia in older adults, and reproductive health management for cancer patients of childbearing age
February 27, 2026
Progress in geriatric oncology, reflections on regulatory complexity, and an exciting new trial in small cell lung cancer
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management
February 19, 2025
Seven ground-breaking findings from cancer clinical trials in 2024 by ECOG-ACRIN and PrECOG
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
March 7, 2024
ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
August 25, 2023
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy.
July 7, 2021
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
July 29, 2020
Currently, there is no treatment standard for metastatic pancreatic cancer in people aged 65 years and older